Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Saved in:
| Title: | Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. |
|---|---|
| Authors: | Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston., Fell G; Dana-Farber Cancer Institute, Harvard Medical School, Boston., Bossuyt V; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Abelman RO; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Wu B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Maheswaran S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Trippa L; Dana-Farber Cancer Institute, Harvard Medical School, Boston., Comander A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Mulvey T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., McLaughlin S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Ryan P; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Ryan L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Abraham E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Rosenstock A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Garrido-Castro AC; Dana-Farber Cancer Institute, Harvard Medical School, Boston., Lynce F; Dana-Farber Cancer Institute, Harvard Medical School, Boston., Moy B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Isakoff SJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Tung N; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston., Mittendorf EA; Brigham and Women's Hospital, Harvard Medical School, Boston., Ellisen LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Ludwig Center, Harvard Medical School, Boston, USA., Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston. Electronic address: Bardia.Aditya@mgh.harvard.edu. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Mar; Vol. 35 (3), pp. 293-301. Date of Electronic Publication: 2023 Dec 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
